162 related articles for article (PubMed ID: 20621035)
21. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
22. Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study.
Lacut K; Larramendy-Gozalo C; Le Gal G; Duchemin J; Mercier B; Gourhant L; Mottier D; Becquemont L; Oger E; Verstuyft C
J Thromb Haemost; 2007 Oct; 5(10):2020-4. PubMed ID: 17883698
[TBL] [Abstract][Full Text] [Related]
23. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
24. miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle.
Pérez-Andreu V; Teruel R; Corral J; Roldán V; García-Barberá N; Salloum-Asfar S; Gómez-Lechón MJ; Bourgeois S; Deloukas P; Wadelius M; Vicente V; González-Conejero R; Martínez C
Mol Med; 2013 Jan; 18(1):1466-72. PubMed ID: 23154637
[TBL] [Abstract][Full Text] [Related]
25. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
[TBL] [Abstract][Full Text] [Related]
26. VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy.
Hammed A; Matagrin B; Spohn G; Prouillac C; Benoit E; Lattard V
J Biol Chem; 2013 Oct; 288(40):28733-42. PubMed ID: 23928358
[TBL] [Abstract][Full Text] [Related]
27. Sequence variation in vitamin K epoxide reductase gene is associated with survival and progressive coronary calcification in chronic kidney disease.
Holden RM; Booth SL; Tuttle A; James PD; Morton AR; Hopman WM; Nolan RL; Garland JS
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1591-6. PubMed ID: 24855061
[TBL] [Abstract][Full Text] [Related]
28. [Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms].
Stępień E; Wypasek E; Branicka A; Undas A
Kardiol Pol; 2010; 68 Suppl 5():S428-35. PubMed ID: 22134997
[TBL] [Abstract][Full Text] [Related]
29. VKORC1 C1173T and VKORC1 G-1639A gene polymorphisms in Turkish Behçet's patients with ocular and non-ocular involvement.
Demir HD; Ortak H; Şahin Ş; Ateş Ö; Benli I; İnanır A
Ophthalmic Genet; 2014 Mar; 35(1):7-11. PubMed ID: 23362849
[TBL] [Abstract][Full Text] [Related]
30. Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study.
Suh JW; Baek SH; Park JS; Kang HJ; Chae IH; Choi DJ; Park HJ; Kim PJ; Seung KB; Kim HS
Am Heart J; 2009 May; 157(5):908-12. PubMed ID: 19376320
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.
Harrington DJ; Underwood S; Morse C; Shearer MJ; Tuddenham EG; Mumford AD
Thromb Haemost; 2005 Jan; 93(1):23-6. PubMed ID: 15630486
[TBL] [Abstract][Full Text] [Related]
32. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study.
Teichert M; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; De Smet PA; Witteman JC; Stricker BH
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):771-6. PubMed ID: 18218987
[TBL] [Abstract][Full Text] [Related]
33. Association of polymorphisms of interleukin-6, osteocalcin, and vitamin D receptor genes, alone or in combination, with bone mineral density in community-dwelling Japanese women and men.
Yamada Y; Ando F; Niino N; Shimokata H
J Clin Endocrinol Metab; 2003 Jul; 88(7):3372-8. PubMed ID: 12843190
[TBL] [Abstract][Full Text] [Related]
34. BMD values and GSTM3 gene polymorphisms in combination with GSTT1/GSTM1 genes: a genetic association study in Slovenian elderly.
Jurkovic Mlakar S; Prezelj J; Osredkar J; Marc J
Gerontology; 2012; 58(3):238-48. PubMed ID: 22327174
[TBL] [Abstract][Full Text] [Related]
35. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
[TBL] [Abstract][Full Text] [Related]
36. Modelling the atypical absorption of menatetrenone and the metabolism to its epoxide: effect of VKORC1 polymorphism.
Baek IH; Kang W; Yun HY; Lee SS; Kwon KI
J Clin Pharm Ther; 2011 Jun; 36(3):390-8. PubMed ID: 21545618
[TBL] [Abstract][Full Text] [Related]
37. VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding.
Spohn G; Kleinridders A; Wunderlich FT; Watzka M; Zaucke F; Blumbach K; Geisen C; Seifried E; Müller C; Paulsson M; Brüning JC; Oldenburg J
Thromb Haemost; 2009 Jun; 101(6):1044-50. PubMed ID: 19492146
[TBL] [Abstract][Full Text] [Related]
38. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
Teichert M; van Schaik RH; Hofman A; Uitterlinden AG; de Smet PA; Stricker BH; Visser LE
Clin Pharmacol Ther; 2009 Apr; 85(4):379-86. PubMed ID: 19225451
[TBL] [Abstract][Full Text] [Related]
39. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Rost S; Fregin A; Ivaskevicius V; Conzelmann E; Hörtnagel K; Pelz HJ; Lappegard K; Seifried E; Scharrer I; Tuddenham EG; Müller CR; Strom TM; Oldenburg J
Nature; 2004 Feb; 427(6974):537-41. PubMed ID: 14765194
[TBL] [Abstract][Full Text] [Related]
40. Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brain.
Caspers M; Czogalla KJ; Liphardt K; Müller J; Westhofen P; Watzka M; Oldenburg J
Thromb Res; 2015 May; 135(5):977-83. PubMed ID: 25747820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
